The primary endpoint was defined as the first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke Novo Nordisk announced top data from the DEVOTE trial confirming the ...

Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an expanded use for Tresiba (insulin degludec) injection to improve glycemic control in children and adolescents with ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...

Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Tresiba ® (insulin degludec injection), a ...

Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...

COPENHAGEN, Nov 29 (Reuters) - Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type ...

Diabetics treated with Novo Nordisk’s basal insulin Tresiba have a lower risk of developing low blood sugar compared to Sanofi’s Lantus, according to a new trial. The SWITCH 2 study found that type 2 ...

New data presented at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba(R) (insulin ...

Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...